Advances in antiplatelet therapies for patients with cardiovascular disease have improved
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …

Cardiovascular disease remains the main cause of mortality in individuals with diabetes
mellitus (DM) and also results in significant morbidity. Premature and more aggressive …

Thrombo-inflammation describes the complex interplay between blood coagulation and
inflammation that plays a critical role in cardiovascular diseases. The third Maastricht …

Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …

Single antiplatelet therapy (SAPT) and intensified antithrombotic regimens (prolonged dual
antiplatelet therapy [DAPT] or dual pathway inhibition [DPI]) are recommended for …

Abstract Aims According to the 2019 European Society of Cardiology (ESC) guidelines on
chronic coronary syndromes (CCS), adding a P2Y12 inhibitor or rivaroxaban to aspirin …

Background Patients with previous acute coronary syndrome (ACS) are at high risk of
recurrent adverse cardiovascular events. Recently, prolonged dual antiplatelet therapy …

There have been numerous and intriguing advancements in antithrombotic therapy for
myocardial infarction since it was described in the earliest issues of Thrombosis and …

Coronary artery disease is a leading cause of morbidity and mortality worldwide. Despite
significant advances in revascularization strategies and antiplatelet therapy with aspirin …

Coronary artery disease and peripheral arterial disease are strong predictors of risk for a
future ischemic event. Despite the utilization of effective secondary prevention strategies, the …